Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.48 |
| ▸ | AXL | P30530 | 12/20 | 0.47 |
| ▸ | MET | P08581 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554493 | 0.87 | HSPB1 (0.50) | HSPB1AXLALDH1A1MAPTMAPK1 | |
| SCHEMBL12405902 | 0.85 | ALDH1A1 (0.41) | HSPB1AXLALDH1A1MAPTMAPK1 | |
| SCHEMBL4817688 | 0.82 | MAP4K4 (0.44) | HSPB1METALDH1A1MAPTMAPK1 | |
| SCHEMBL31554532 | 0.81 | HSPB1 (0.44) | HSPB1AXLALDH1A1MAPTMAPK1 | |
| SCHEMBL1396331 | 0.81 | ATM (0.45) | HSPB1AXLMETALDH1A1MAPT | |
| SCHEMBL3484559 | 0.81 | KMT2A (0.56) | HSPB1AXLALDH1A1MAPTMAPK1 | |
| SCHEMBL16863203 | 0.80 | AXL (0.47) | HSPB1AXLMETALDH1A1MAPT | |
| SCHEMBL18199832 | 0.80 | HSPB1 (0.45) | HSPB1AXLMETALDH1A1MAPT | |
| SCHEMBL16863400 | 0.80 | HSPB1 (0.48) | HSPB1AXLALDH1A1MAPTMAPK1 | |
| SCHEMBL1962922 | 0.80 | HSPB1 (0.45) | HSPB1AXLALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042905-B1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | WELLMARKER BIO CO LTD (KR) | 2020-06-17 | — | — | EP | disclosed |
| US-9815840-B2 | Protein kinase inhibitor containing pyrrolopyridazine derivative | THE ASAN FOUNDATION (KR) | 2017-11-14 | — | — | US | disclosed |
| US-9815840-B2 | Protein kinase inhibitor containing pyrrolopyridazine derivative | THE ASAN FOUNDATION (KR) | 2017-11-14 | — | — | US | disclosed |
| US-9815840-B2 | Protein kinase inhibitor containing pyrrolopyridazine derivative | THE ASAN FOUNDATION (KR) | 2017-11-14 | — | — | US | disclosed |
| US-20160207931-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | CJ HEALTHCARE CORPORATION (KR) | 2016-07-21 | — | — | US | disclosed |
| US-20160207931-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | CJ HEALTHCARE CORPORATION (KR) | 2016-07-21 | — | — | US | disclosed |
| US-20160207931-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | CJ HEALTHCARE CORPORATION (KR) | 2016-07-21 | — | — | US | disclosed |
| EP-3042905-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | CJ Healthcare Corporation (KR) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015034213-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | 씨제이헬스케어 주식회사 (KR) | 2015-03-12 | — | — | WO | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| EP-1768983-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | HSPB1 2930/4885AXL 452/4885MET 721/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | HSPB1 2677/4885AXL 880/4885MET 2109/4885 |
| US-20160207931-A1 | PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE | MAPKAPK5, MAP3K5, PRKCA | HSPB1 1364/4885AXL 1559/4885MET 1763/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | HSPB1 2930/4885AXL 452/4885MET 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.